Methods for conducting international Delphi surveys to optimise global participation in core outcome set development: a case study in gastric cancer informed by a comprehensive literature review.
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
21 Jun 2021
21 Jun 2021
Historique:
received:
07
12
2020
accepted:
21
05
2021
entrez:
22
6
2021
pubmed:
23
6
2021
medline:
24
6
2021
Statut:
epublish
Résumé
Core outcome sets (COS) should be relevant to key stakeholders and widely applicable and usable. Ideally, they are developed for international use to allow optimal data synthesis from trials. Electronic Delphi surveys are commonly used to facilitate global participation; however, this has limitations. It is common for these surveys to be conducted in a single language potentially excluding those not fluent in that tongue. The aim of this study is to summarise current approaches for optimising international participation in Delphi studies and make recommendations for future practice. A comprehensive literature review of current approaches to translating Delphi surveys for COS development was undertaken. A standardised methodology adapted from international guidance derived from 12 major sets of translation guidelines in the field of outcome reporting was developed. As a case study, this was applied to a COS project for surgical trials in gastric cancer to translate a Delphi survey into 7 target languages from regions active in gastric cancer research. Three hundred thirty-two abstracts were screened and four studies addressing COS development in rheumatoid and osteoarthritis, vascular malformations and polypharmacy were eligible for inclusion. There was wide variation in methodological approaches to translation, including the number of forward translations, the inclusion of back translation, the employment of cognitive debriefing and how discrepancies and disagreements were handled. Important considerations were identified during the development of the gastric cancer survey including establishing translation groups, timelines, understanding financial implications, strategies to maximise recruitment and regulatory approvals. The methodological approach to translating the Delphi surveys was easily reproducible by local collaborators and resulted in an additional 637 participants to the 315 recruited to complete the source language survey. Ninety-nine per cent of patients and 97% of healthcare professionals from non-English-speaking regions used translated surveys. Consideration of the issues described will improve planning by other COS developers and can be used to widen international participation from both patients and healthcare professionals.
Sections du résumé
BACKGROUND
BACKGROUND
Core outcome sets (COS) should be relevant to key stakeholders and widely applicable and usable. Ideally, they are developed for international use to allow optimal data synthesis from trials. Electronic Delphi surveys are commonly used to facilitate global participation; however, this has limitations. It is common for these surveys to be conducted in a single language potentially excluding those not fluent in that tongue. The aim of this study is to summarise current approaches for optimising international participation in Delphi studies and make recommendations for future practice.
METHODS
METHODS
A comprehensive literature review of current approaches to translating Delphi surveys for COS development was undertaken. A standardised methodology adapted from international guidance derived from 12 major sets of translation guidelines in the field of outcome reporting was developed. As a case study, this was applied to a COS project for surgical trials in gastric cancer to translate a Delphi survey into 7 target languages from regions active in gastric cancer research.
RESULTS
RESULTS
Three hundred thirty-two abstracts were screened and four studies addressing COS development in rheumatoid and osteoarthritis, vascular malformations and polypharmacy were eligible for inclusion. There was wide variation in methodological approaches to translation, including the number of forward translations, the inclusion of back translation, the employment of cognitive debriefing and how discrepancies and disagreements were handled. Important considerations were identified during the development of the gastric cancer survey including establishing translation groups, timelines, understanding financial implications, strategies to maximise recruitment and regulatory approvals. The methodological approach to translating the Delphi surveys was easily reproducible by local collaborators and resulted in an additional 637 participants to the 315 recruited to complete the source language survey. Ninety-nine per cent of patients and 97% of healthcare professionals from non-English-speaking regions used translated surveys.
CONCLUSION
CONCLUSIONS
Consideration of the issues described will improve planning by other COS developers and can be used to widen international participation from both patients and healthcare professionals.
Identifiants
pubmed: 34154641
doi: 10.1186/s13063-021-05338-x
pii: 10.1186/s13063-021-05338-x
pmc: PMC8218463
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
410Subventions
Organisme : Department of Health
ID : DRF-2015-08-023
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K025643/1
Pays : United Kingdom
Organisme : National Institute for Health Research
ID : DRF-2015-08-023
Investigateurs
Shuangxi Li
(S)
Yu-Long He
(YL)
Zekuan Xu
(Z)
Yingwei Xue
(Y)
Han Liang
(H)
Guoxin Li
(G)
Enhao Zhao
(E)
Philipp Neumann
(P)
Linda O'Neill
(L)
Emer Guinan
(E)
Gian Luca Baiocchi
(GL)
Giovanni de Manzoni
(G)
Eliza R C Hagens
(ERC)
Mark I van Berge Henegouwen
(MI)
Patrícia Lages
(P)
Susana Onofre
(S)
Gabriel Salcedo Cabañas
(GS)
Maria Posada Gonzalez
(MP)
Cristina Marin Campos
(CM)
Bahar Candas
(B)
Bahadır Emre Baki
(BE)
Muhammed Selim Bodur
(MS)
Reyyan Yildirim
(R)
Arif Burak Cekic
(AB)
Jean-Baptiste Beuscart
(JB)
Sophie Horbach
(S)
Christopher Mecoli
(C)
Toby O Smith
(TO)
Références
Gastric Cancer. 2019 Jan;22(1):172-189
pubmed: 29846827
Lancet Gastroenterol Hepatol. 2018 Dec;3(12):865-873
pubmed: 30507470
BMJ Open. 2018 Oct 17;8(10):e021796
pubmed: 30337308
Expert Rev Pharmacoecon Outcomes Res. 2017 Dec;17(6):523-530
pubmed: 28974101
Trials. 2017 Jun 20;18(Suppl 3):280
pubmed: 28681707
J Clin Epidemiol. 2018 Apr;96:84-92
pubmed: 29288712
Implement Sci. 2018 May 29;13(1):72
pubmed: 29843737
Br J Dermatol. 2018 Feb;178(2):473-481
pubmed: 28986976
PLoS One. 2018 Dec 28;13(12):e0209869
pubmed: 30592741
Value Health. 2005 Mar-Apr;8(2):94-104
pubmed: 15804318
BMC Med. 2018 Feb 13;16(1):21
pubmed: 29433501
J Rheumatol. 2019 Aug;46(8):981-989
pubmed: 30647185
BMJ Open. 2020 Feb 12;10(2):e034782
pubmed: 32051319
J Rheumatol. 2017 Nov;44(11):1683-1687
pubmed: 28765245
Trials. 2017 Aug 9;18(1):370
pubmed: 28793921